Indication intelligence, analysis and sector perception

Intrexon (XON), Fate (FATE), Kite (KITE) – Changes in the C-Suites

May 17, 2016 10:18am

Germano named president of XON, Stogardt becomes chief medical officer at FATE, Jenkinson joins Kite Pharma (KITE) as chief financial officer

Intrexon named Geno Germano to the newly created role of president, effective June 1, 2016. Germano will help lead XON’s management team and commercialization efforts utilizing XON’s technology platform for biologically-based solutions across a broad range of industries. Each of XON’s five sectors and the office of the chief operating officer will report to Germano. Germano joins XON from Pfizer's (NYSE: PFE) Global Innovative Pharma Business, where he led a $14 B business with market-leading medicines and a broad portfolio of late-stage development candidates in several therapeutic areas including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases.

Fate Therapeutics (FATE) named Dr. Chris Stogard chief medical officer, where he will lead the design and execution of clinical trials for FATE’s programmed cellular immunotherapies. He most recently served as vice president of Clinical Research and development at Ardea Biosciences, a member of the AstraZeneca Group. Dr. Storgard led the ZURAMPIC® global clinical program to successful U.S. and European regulatory approvals.

Kite Pharma (KITE) appointed Paul Jenkinson as chief financial officer. He most recently served as vice president, Global Commercial and Corporate Finance at Allergan (AGN) where he was responsible for the corporation’s financial planning and analysis activities, working with commercial operations, manufacturing operations, research and development, and general and administration functions in multiple international markets.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.